Supernus Announces Issuance of Sixth U.S. Patent Protecting Trokendi XR(R)
April 02 2015 - 4:30PM
Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced the issuance on March 31, 2015 of a sixth patent
(number 8,992,989) by the United States Patent and Trademark Office
(USPTO) covering Trokendi XR, its novel once-daily extended-release
topiramate product. The patent provides protection for the product
with expiration that is no earlier than 2027.
"We are very serious about securing intellectual property
protection for our innovative products. We will continue to build
our patent estate to provide our products with the protection they
are entitled to. We now have patent protection on Oxtellar XR® and
Trokendi XR® through four and six issued U.S. patents,
respectively," said Jack A. Khattar, President and CEO of
Supernus.
Supernus has several additional patent applications for
extended-release topiramate and extended-release oxcarbazepine
pending in other geographic regions.
About Trokendi XR
Trokendi XR is the first approved novel once-daily extended
release formulation of topiramate for the treatment of epilepsy.
Trokendi XR is an antiepileptic drug indicated for initial
monotherapy in patients 10 years of age and older with partial
onset or primary generalized tonic-clonic seizures; adjunctive
therapy in patients 6 years of age and older with partial onset or
primary generalized tonic-clonic seizures; and adjunctive therapy
in patients 6 years of age and older with seizures associated with
Lennox-Gastaut syndrome. The product is available in 25mg, 50mg,
100mg and 200mg extended-release capsules.
For full prescribing and safety
information, click
here.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system, or CNS, diseases. The Company
markets two products for epilepsy, Oxtellar XR (extended-release
oxcarbazepine) and Trokendi XR (extended-release topiramate). The
Company is also developing several product candidates in psychiatry
to address large market opportunities in ADHD, including ADHD
patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for
ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding
the potential of Trokendi XR and Oxtellar XR and intellectual
property protection. Actual results may differ materially from
those in these forward-looking statements as a result of various
factors, including, but not limited to, risks regarding the
company's ability to commercialize the product successfully,
whether physicians will prescribe and patients will use the
product, and competition in the market. For a further description
of these and other risks facing the Company, please see the risk
factors described in the Company's Annual Report Form 10-K that was
filed with the United States Securities and Exchange Commission on
March 12, 2015 and under the caption "Risk Factors".
Forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to update or
revise these statements, except as may be required by law.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
INVESTOR CONTACT:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Sep 2023 to Sep 2024